Vol. 3 No. 7 (2023)
Reimbursement Reviews

Fostemsavir (Rukobia)

Published July 26, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses fostemsavir (Rukobia), 600 mg, extended-release tablets, oral.
  • Indication: For adults with HIV-1 who are heavily treatment-experienced and have multidrug-resistant HIV-1, and for whom it is otherwise not possible to construct a suppressive antiviral regimen due to resistance, intolerance, or safety considerations.